The Pharmaceutical Journal
Vol 275 No 7369 p401
1 October 2005

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Rapid acting insulin analogue effective in a range of body types launched

New rapid acting insulin analogue insulin glulisine has been launched by Aventis Pharma this week.

Aventis Pharma says that insulin glulisine (Apidra) has a faster onset of action in people with body mass indices ranging from lean to obese, compared with rapid acting insulin analogue, insulin lispro.

The company adds that insulin glulisine provides equivalent reductions to insulin lispro in HbA1c in people with type 1 or type 2 diabetes.

Insulin glulisine is aimed at people with type 1 and type 2 diabetes who require a basal-bolus insulin regimen. It should be given no more than 15 minutes before or soon after meals. It should be used with an intermediate- or long-acting insulin or basal insulin analogue and can be used with oral hypoglycaemics.